Comparison of Procalcitonin Level in Normal Population and in Chronic Kidney Disease Patients Who Don't Have Infection

Not Applicable

Not yet recruiting

• Conditions: Chronic Kidney Disease Patients Who Don't Have Infection
• Interventions: Diagnostic Test: procalcitonin

• Registration Number: NCT05585970
• Lead Sponsor: Sohag University

Brief Summary

Chronic kidney disease (CKD) is a life threatening condition with high risk of pre-term death and need for dialysis. It is defined as kidney damage that has continued for more than 3 months as characterized by structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR). It is also defined as GFR \< 60mL/min/1.73 m2 for more than 3 months, with or without structural kidney damage.

The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens. However, due to the pre-existing endogenous inflammation that occurs in CKD patients and the impaired kidney clearance, the reference range that applies to the general population may not be appropriate for diagnosing infections in CKD patients. More recently, debate has continued regarding whether the PCT level is increased in CKD patients without infection, and the optimal reference for CKD patients remains undetermined

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2022-10
• Study First Submitted: 2022-10-16
• Study First Submitted QC: 2022-10-18
• Last Update Submitted: 2022-10-18
• Study First Posted: 2022-10-19
• Last Update Posted: 2022-10-19
• Study Start: 2022-11-01
• Primary Completion: 2023-05-01
• Study Completion: 2023-05-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• Chronic Kidney Disease patients.
• ESRD patients

Read More

Exclusion Criteria

Any condition of infection or sepsis such as :

• Fever
• Increased TLC above normal
• Tachycardia
• Tachypnea
• Disturbed conscious level

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
healthy Control individuals	procalcitonin	-
CKD patients	procalcitonin	-
ESRD on regular hemodialysis	procalcitonin	-

Primary Outcome Measures

Name	Time	Method
procalcitonin Level	6 months

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt